BTE 2.98    Updated: 04-20-2017 $BTE Last Trade:

New Post Public Reply Private Reply Replies (0) Message Board
stockcharts
32
BTE 2.98    Updated: 04-20-2017 $BTE
Last Trade: 4/20/2017
Last 2.98   
Open 3.12
Previous Close 2.98
Day High / Low 3.14 / 2.97
Year High / Low 7.14 / 2.97
Volume 2,450,515
Projected Volume 2450515 (131%)
# of Trades / Projected 1,391 / 1,391
Dividend / Yield - / 0.00%
Abnormal Activity NONE
Abnormal Volume NO
Gap NONE
Candle BEARISH
Volatility Today LOW
Volatility Yesterday LOW
Price Relativity
From 40 Day High 81%
From 80 Day High 65%
From 150 Day High 60%
From 40 Day Low 104%
From 80 Day Low 104%
From 150 Day Low 104%
Pivot Analysis
Price Pivot $ 3.28
Day Resistance 1 $ 3.29
Day Support 1 $ 3.25
Day Resistance 2 $ 3.32
Day Support 2 $ 3.24
Consolidations
Short Term YES
Medium Term YES
Long Term YES
Volume Indicators
20 Day Avg Vol 1,873,077
Today / 20 Day Avg Vol BELOW
150 Day Avg Vol 2,541,706
Today / 150 Day Avg Vol BELOW
Abnormal Volume NO
William Volume Accumulation bearish
Volume Price Trend bearish
Momentum Indicators
10 Day Trend bearish
40 Day Trend bearish
100 Day Trend bearish
Stochastics bearish
RSI bearish
MACD bearish
Moving Average Indictors
15 Day Trend bearish
45 Day Trend bearish
100 Day Trend bearish
Mid Term Moving Average Crossover NONE
Long Term Moving Average Crossover NONE
Volatility Indicators
Abnormal Activity Today? NONE
Volatility Index Today LOW
Volatility Index Yesterday LOW
10 Day Volatility DECREASING
20 Day Volatility DECREASING
40 Day Volatility DECREASING

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Ipsen's Kayfanda® Receives EU Approval for Alagille Syndrome Treatment

Updated Category News Views 67

Kayfanda® Receives Approval for Treatment in the EU Ipsen has made a noteworthy advancement in pediatric healthcare with the recent authorization of Kayfanda® (odevixibat) in the European Union (EU). This innovative treatment specifically addresses cholestatic pruritus, a painful symptom linked to Alagille Syndrome, a rare liver disorder that affects children. This...

Continue Reading
Discover the Remarkable Returns of Vulcan Materials Stock

Updated Category News Views 144

Unveiling Vulcan Materials Company Stock Performance Vulcan Materials Co. (NYSE: VMC) has been a noteworthy performer in the stock market over the past 15 years, surpassing market expectations with a commendable annual return of 15.1%. This stock has consistently outperformed the market, achieving an admirable 2.86% advantage annually. With a current market capitalization...

Continue Reading
AeroPress Launches Premium Coffee Press with Elegant Design

Updated Category News Views 332

AeroPress introduced its Premium coffee press back in 2024, and you can bet the market was watching closely. With a retail price of $149.95, this isn’t just another brewing tool; it’s a statement piece designed for those who take their morning ritual seriously. Traders buzzed about how this could impact sales in a saturated market where every new gadget fights for...

Continue Reading
Investigation Update: Walgreens Boots Alliance Class Action Lawsuit

Updated Category News Views 327

Overview of the Walgreens Boots Alliance Class Action Levi & Korsinsky, LLP has raised awareness among investors regarding a class action securities lawsuit involving Walgreens Boots Alliance, Inc. This company, known for its extensive pharmaceutical and retail operations, is currently facing legal challenges that could significantly impact its investors. Class Definition...

Continue Reading
Savillex Strengthens Market Position with New Acquisition

Updated Category News Views 38

Savillex Acquires Optimum Processing to Enhance Offerings Thompson Street Capital Partners (TSCP) is proud to announce that its portfolio company, Savillex, has completed the acquisition of Optimum Processing, Inc. This strategic move is expected to elevate Savillex's position in the marketplace by combining its innovative fluid handling solutions with Optimum...

Continue Reading